MD Anderson's The Art and Science of Managing the New Melanoma Landscape 2020
M

2020 Updates on BRAFV600-Mutant Melanoma: FDA-Approved BRAFi + MEKi Regimens vs. BRAFi Mono - What Are the Long-Term PFS/OS Outcomes?

By MD Anderson's The Art and Science of Managing the New Melanoma Landscape 2020 FEATURING Michael Davies
By MD Anderson's The Art and Science of Managing the New Melanoma Landscape 2020 FEATURING Michael Davies
194 views
November 19, 2020
0 Comments
Login to view comments. Click here to Login

Related Content

AUTOPLAY
10:01
AAD 2024 Insights

AAD 2024 Insights: The Latest Advances in the Treatment of Melanoma

Feat. V. Sondak
12:46
Stanford Medicine

FDA Approval of Lifileucel for Unresectable or Metastatic Melanoma: …

Feat. A. Betof Warner
24:14
Masterclasses in Dermatology

Advances in the Treatment of Melanoma

Feat. D. Fisher
05:37
Melanoma Bridge 2023

COLUMBUS 7-Year Update: Encorafenib + Binimetinib vs. Vemurafenib or…

Feat. R. Dummer
18:21
Vanderbilt University Medical Center (VUMC)

NCCN Guidelines Updates for the Management of Cutaneous Melanoma: Ne…

Feat. D. Johnson
20:55
2023 West Oncology Conference

2023 West Oncology Conference: Melanoma Updates

Feat. M. Mooradian
04:45
Sapna Patel

Optimal Duration of Neoadjuvant Treatment in Melanoma: What We Do No…

20:32
Melanoma Bridge 2023

Targeted Therapy in BRAF-Mutated Metastatic Melanoma

Feat. R. Dummer
13:31
Melanoma Bridge 2023

What Is the Best Initial Treatment for Unresectable Mucosal Melanoma…

Feat. J. Luke
17:32
Insights from 2023 Society for Melanoma Research Annual Meeting

2023 SMR Congress Insights: "DREAMseq Trial Final 2-year OS Dat…

Feat. M. Atkins
24:22
Total Health

2022 Sedona Melanoma Updates From ASCO: Overview and Treatment

Feat. K. Lewis
21:38
Penn Medicine Abramson Cancer Center

Updates in Systemic Therapy for Melanoma

Feat. T. Mitchell
13:20
Penn Medicine Abramson Cancer Center

Penn Medicine Updates in Oncology 2023: Melanoma

Feat. J. Cohen
10:39
Moffitt Cancer Center

Clinical Implications of COMBI-d and COMBI-v Trials on OS in Patient…

Feat. A. Tarhini
27:29
Total Health

2023 ASCO® Direct Philadelphia: Melanoma Updates

Feat. M. Orloff
13:55
Northwestern Medicine Oncology and Hematology

Utilization of COMBI-APlus Data in Clinical Practice: Adapted Pyrexi…

Feat. S. Chandra
07:53
Insights from 2023 ESMO Annual Meeting

ESMO 2023 Insights: "aTezolizumab, bevAcizumab, and Cobimetinib…

Feat. E. Burton
15:38
Melanoma Bridge 2023

New Interesting Targets From Recent Melanoma Research

Feat. O. Hamid
12:09
Omid Hamid

Evolving Management of Melanoma CNS Metastases and the Impact of COM…

16:14
Kim Margolin

Highlights From the Recent Melanoma Research Alliance Meeting: What&…